Oral squamous cell carcinoma during long-term treatment with hydroxyurea

Benedittis, M. De; Petruzzi, Massimo; Giardina, C; Muzio, Lorenzo Lo; Favia, Gianfranco; Serpico, Rosario

doi:10.1111/j.1365-2230.2004.01586.x

Cited by 26 publications

(20 citation statements)

References 11 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are yet other hypothetical pathways not involving DNhpom. For example the involvement of hydroxyurea -an important drug for inducing HbF biosynthesis (Atweh et al, 2003), which like DNA demethylation agents may promotes carcinogenesis (De Benedittis et al, 2004). Another aspect of the abundance of F-cells inside these tumours is related to their embryonic characteristics.…”

Section: Discussionmentioning

confidence: 99%

Foetal haemoglobin-blood cells (F-cells) as a feature of embryonic tumours (blastomas)

2007

View full text Add to dashboard Cite

Tumour markers are important in the diagnosis and monitoring of many tumours. This study tested the hypothesis that an oncofoetal protein, foetal haemoglobin (HbF) is a potential tumour marker in embryonic tumours, useful for management. An immunohistochemical investigation of HbF blood cell (Fc) distribution was carried out in tumours and in bone marrow samples from 83 children and 13 adults with various embryonic tumours (blastomas), and in bone marrow samples of 24 leukaemia patients. In the three, main blastoma types, nephroblastoma (Wilms' tumour), neuroblastoma and retinoblastoma, where all the patients, except two, were children, around 80% of the tumour samples had Fc within proliferating blood vessels and spaces between tumour cells. In parallel, clusters of Fc, mostly F-erythroblasts (Feb), were distributed in the bone marrow of some of those patients and in the bone marrow of 79% of the leukaemia patients. Foetal haemoglobin, as well as being a potential prognostic cancer marker, is a potential indicator of DNA hypomethylation implicated in the development of these tumours, as well as in others previously noted for the presence of HbF.

show abstract

Section: Discussionmentioning

confidence: 99%

Foetal haemoglobin-blood cells (F-cells) as a feature of embryonic tumours (blastomas)

2007

View full text Add to dashboard Cite

show abstract

“…The literature review of patients with CML [4,5] and other myelogenous disorders on treatment with hydroxyurea revealed that oral cancer following long-term treatment with hydroxyurea has been reported only in a few instances, once in a patient with concomitant multiple skin tumors and the other instance in a patient with polycythemia vera who developed oral cancer after 15 years of hydroxyurea therapy [6]. There is no reported correlation between the onset of this complication to the dose and duration of therapy.…”

Section: Discussionmentioning

confidence: 99%

Oral Cavity Squamous Cell Carcinoma in a Case of Ifap Syndrome With Chronic Myeloid Leukemia on Long Term Hydroxyurea: A Rare Presentation

Singh

Reddy

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

We report a case of a patient in his early 30s who presented with an ulceroproliferative growth over the left buccal mucosa; he was also on treatment for chronic myeloid leukemia in blast crisis on hydroxyurea and a known case of ichthyosis follicularis, alopecia, and photophobia syndrome. Although a working diagnosis of chloroma/hydroxyurea-induced erosive lichen planus was suspected, the histopathological examination of the lesion was suggestive of squamous cell carcinoma. He was subsequently planned for palliative radiotherapy.

show abstract

“…This may be due to the fact that oral mucosa, unlike skin, is not exposed to chronic ultraviolet irradiation. 22 In our case, the patient recieved hydroxyurea therapy for 48 months at a dose of 1500 mg (3x500mg) daily. Best et al (1998) reported two cases with myeloproliferative diseases who developed multiple skin cancers after long term therapy with hydroxyurea which the cumulative dose was 3958 grams.…”

Section: Discussionmentioning

confidence: 99%

“…22 MDe Benedditis et al reported a polycythemia vera case, who developed oral squamous cell carcinoma without any known risk factors, after recieving a cumulative dose of 6255 grams of hydroxyurea therapy throughout 15 years. 22 Oral squamous cell carcinoma secondary to hydroxyurea therapy occurs after more prolonged treatment with higher cumulative doses of hydroxyurea than happens with skin tumors. This may be due to the fact that oral mucosa, unlike skin, is not exposed to chronic ultraviolet irradiation.…”

Section: Discussionmentioning

confidence: 99%

“…23 MDe Benedditis et al listed 23 available reported cases in litterature with cutaneous squamous and basal cell carcinomas and oral cancer which were affected by CML essential thrombocytopenia and polycythemia vera who recieved long term therapy with hydroxyurea mentioning their underlying diseases, ages, duration and cumulative dose of treatment with hydroxyurea. 22 When we evaluate this list, we see variable cumulative doses of hydroxyurea, and variable duration of treatment with hydroxyurea. This result tells us that, age of the patient, history of the patient, like smoking and, risk factors, like UV rays, sun exposure and, other variables must be important additional factors in determining the time when skin or oral malignancies will develop.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Squamous Cell Carcinoma Accompanying Chronic Myeloid Leukemia: Case Report and Review of the Literature

Kılınç¹,

Tenekeci²,

Bilen³

2012

JIUMF

View full text Add to dashboard Cite

Background: Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder characterized by, overproduction of myeloid cells. Hydroxyurea is an antimetabolite which is commonly used in myeloproliferative syndromes. Reported skin changes related to hydroxyurea therapy may range form xerosis to mucocutaneous cancers. Aim: In this study, our aim was to understand and discuss the underlying reason for the development of squamous cell carcinoma (SCC) in patients recieving hydroxyurea and present a case, in whomwe operated to excise the tumoral masses and reconstruct them. Materials and Methods: After recieving hydroxyuea therapy for four years, the patient was diagnosed as squamous cell carcinoma on the upper lip and, on the dorsum of the left hand. She was operated and the tumoral masses were excised. The lesion on the upper lip was reconstructed with nasolabial flap, inner and inferior sides of the flap was skin grafted. The defect on the dorsum of the hand was skin grafted. Results: No complication related to operation occured. Throughout postoperative eight months of follow-up period, the patient had no complaint regarding the operation. Conclusıon: Skin lesions of patients recieving hydroxyurea therapy must be carefully examined and monitored regularly, since these lesions may proceed to skin cancers.

show abstract

Oral squamous cell carcinoma during long-term treatment with hydroxyurea

Cited by 26 publications

References 11 publications

Foetal haemoglobin-blood cells (F-cells) as a feature of embryonic tumours (blastomas)

Foetal haemoglobin-blood cells (F-cells) as a feature of embryonic tumours (blastomas)

Oral Cavity Squamous Cell Carcinoma in a Case of Ifap Syndrome With Chronic Myeloid Leukemia on Long Term Hydroxyurea: A Rare Presentation

Squamous Cell Carcinoma Accompanying Chronic Myeloid Leukemia: Case Report and Review of the Literature

Contact Info

Product

Resources

About